Compare Amylx Pharmaceuticals Inc (AMLX) vs T Rowe Price Group Inc (TROW) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

T. Rowe Price (TROW) trades at $114.02, up 0.35% today, with a neutral technical outlook and mixed analyst sentiment. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51, driven by record assets under management and higher advisory fees. The stock trades at a P/E of 11.45, below industry averages, indicating potential undervaluation. Dividend payments remain stable at $1.30 per share, supporting income investors.

Outlook is cautiously optimistic given strong profitability metrics like a 29.26% net income margin and 20.1% ROE, but risks include expense pressures and net outflows. Analyst consensus price target is $112.17, slightly below current price, with 63% hold ratings suggesting limited near-term upside. Investors should weigh solid fundamentals against competitive headwinds in the asset management sector.